Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: A cross-sectional study in the chronic renal insufficiency cohort (CRIC)

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Dubin, Ruth F ^a   Li, Yongmei ^a   He, Jiang ^b   Jaar, Bernard G ^c   Kallem, Radhakrishna ^d   Lash, James P ^e   Makos, Gail ^f   Rosas, Sylvia E ^d   Soliman, Elsayed Z ^g   Townsend, Ray R ^d   Yang, Wei ^h   Go, Alan S ⁱ   Keane, Martin ^d   Defilippi, Christopher ^j   Mishra, Rakesh ^a   Wolf, Myles ^k   Shlipak, Michael G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TULANE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f St John's Health System   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ DIVISION OF RESEARCH   (United States)

^j UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^k UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Cardiovascular disease; Chronic kidney disease; Troponin T

Indexed keywords

ALBUMIN; CREATININE; TROPONIN T;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEGRO; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SENESCENCE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TROPONIN T; UNITED STATES;

EID: 84886931718     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-229     Document Type: Article

References (37)

1. Cystatin C concentration as a risk factor for heart failure in older adults. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG, Cardiovascular Heatlh Study, Ann Intern Med 2005 142 497 505 10.7326/0003-4819-142-7-200504050-00008 15809461
2. Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the atherosclerosis risk in communities (ARIC) study. Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, Coresh J, Am J Kidney Dis 2012 60 207 216 10.1053/j.ajkd.2012.03.011 22537422
3. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the heart and soul study. Ix JH, Shlipak MG, Chertow GM, Whooley MA, Circulation 2007 115 173 179 10.1161/CIRCULATIONAHA.106.674358 17190862 (Pubitemid 46294749)
4. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK, JAMA 2010 304 2503 2512 10.1001/jama.2010.1768 21139111
5. Prediction of outcome by highly sensitive troponin T in outpatients with chronic systolic left ventricular heart failure. Egstrup M, Schou M, Tuxen CD, Kistorp CN, Hildebrandt PR, Gustafsson F, Faber J, Goetze JP, Gustafsson I, Am J Cardiol 2012 110 552 557 10.1016/j.amjcard.2012.04.033 22579083
6. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN, ValHeFT Investigators, Circulation 2007 116 1242 1249 10.1161/CIRCULATIONAHA.106.655076 17698733 (Pubitemid 47517535)
7. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the trial to reduce cardiovascular events with aranesp (darbepoetin-alfa) therapy (TREAT). McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, Parfrey P, Parving HH, Toto RM, Solomon SD, Pfeffer MA, Am Heart J 2011 162 748 755 e3 10.1016/j.ahj.2011.07.016 21982669
8. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, Bakker SJ, Gansevoort RT, PREVEND study group, Eur Heart J 2012 33 2272 2281 10.1093/eurheartj/ehs163 22740385
9. Prediction of ESRD and death among people with CKD: the chronic renal impairment in birmingham (CRIB) prospective cohort study. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, Ferro CJ, Vickery S, Ayrton P, Nair D, Dalton RN, Lamb EJ, Baigent C, Townend JN, Wheeler DC, Am J Kidney Dis 2010 56 1082 1094 10.1053/j.ajkd.2010.07.016 21035932
10. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE, Clin Chim Acta 2010 411 936 939 10.1016/j.cca.2010.03.004 20298685
11. CRIC study investigators. Association of cardiac troponin T with left ventricular structure and function in CKD. Mishra RK, Li Y, Defilippi C, Fischer MJ, Yang W, Keane M, Chen J, He J, Kallem R, Horwitz EJ, Rafey M, Raj DS, Go AS, Shlipak MG, Am J Kidney Dis 2013 61 701 709 10.1053/j.ajkd.2012.11.034 23291148
12. The chronic renal insufficiency cohort (CRIC) study: design and methods. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER 3rd, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators, JASN 2003 14 148 S153 10.1097/01.ASN.0000070149.78399.CE 12819321
13. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondhemier J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, JAMA 2011 305 2432 2439 10.1001/jama.2011.826 21673295
14. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, Warram JH, J Am Soc Nephrol 2005 16 1404 1412 10.1681/ASN.2004100854 15788478 (Pubitemid 41716524)
15. Cystatin C and the risk of death and cardiovascular events among elderly persons. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C, N Engl J Med 2005 352 2049 2060 10.1056/NEJMoa043161 15901858 (Pubitemid 40664306)
16. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF, JASN 2006 17 254 261 16267155
17. Measured GFR does not outperform estimated GFR in predicting CKD-related complications. Hsu CY, Propert K, Xie D, Hamm L, He J, Miller E, Ojo A, Shlipak M, Teal V, Townsend R, Weir M, Wilson J, Feldman H, CRIC Investigators, JASN 2011 22 1931 1937 10.1681/ASN.2010101077 21921144
18. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD, Zhang YL, Greene T, Levey AS, Am J Kidney Dis 2008 51 395 406 10.1053/j.ajkd.2007.11.018 18295055 (Pubitemid 351273480)
19. Recommendations for chamber quantification: a report from the american society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. JASE 2005 18 1440 1463 (Pubitemid 41821197)
20. Analytical validation of a high-sensitivity cardiac troponin T assay. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA, Clin Chem 2010 56 254 261 10.1373/clinchem.2009.132654 19959623
21. A sensitive cardiac troponin T assay in stable coronary artery disease. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski JM, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E, N Engl J Med 2009 361 2538 2547 10.1056/NEJMoa0805299 19940289
22. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, Maggioni AP, Tavazzi L, Tognoni G, Cohn JN, Latini R, Circulation 2012 125 280 288 10.1161/CIRCULATIONAHA.111.044149 22139751
23. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kajimoto H, Kai H, Aoki H, Yasuoka S, Anegawa T, Aoki Y, Ueda S, Okuda S, Imaizumi T, Kidney Int 2012 81 762 768 10.1038/ki.2011.476 22297680
24. What we know about oxidative stress in patients with chronic kidney disease on dialysis-clinical effects, potential treatment, and prevention. Del Vecchio L, Locatelli F, Carini M, Semin Dial 2011 24 56 64 10.1111/j.1525-139X. 2010.00819.x 21299632
25. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Diris JH, Hackeng CM, Kooman JP, Pinto YM, Hermens WT, van Dieijen-Visser MP, Circulation 2004 109 23 25 10.1161/01.CIR.0000113713. 67092.C5 14691043 (Pubitemid 38056015)
26. Left ventricular hypertrophy is more prevalent in blacks than whites in the general population: the Dallas heart study. Drazner MH, Dries DL, Peshock RM, Cooper RS, Klassen C, Kazi F, Willett D, Victor RG, Hypertension 2005 46 124 129 10.1161/01.HYP.0000169972.96201.8e 15939807 (Pubitemid 40946502)
27. Left ventricular mass index and diastolic filling. Relation to blood pressure and demographic variables in a healthy biracial sample. Hinderliter AL, Light KC, Willis PW, Am J Hypertens 1991 4 579 585 1873012
28. Differences in determinants of left ventricular mass assessed by cardiac magnetic resonance imaging across subjects with and without previous symptomatic atherosclerotic disease. Meijs MF, Bots ML, Cramer MJ, Vonken EJ, Velthuis BK, van der Graaf Y, Spiering W, Mali WP, Doevendans PA, Int J Cardiol 2010 138 145 150 10.1016/j.ijcard.2008.08.008 18804881
29. Brachial vascular reactivity in blacks. Perregaux D, Chaudhuri A, Rao S, Airen A, Wilson M, Sung BH, Dandona P, Hypertension 2000 36 866 871 10.1161/01.HYP.36.5.866 11082158
30. Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans. Campia U, Choucair WK, Bryant MB, Waclawiw MA, Cardillo C, Panza JA, J Am Coll Cardiol 2002 40 754 760 10.1016/S0735-1097(02) 02015-6 12204507 (Pubitemid 34925623)
31. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffman U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M, Circulation 2009 119 2545 2552 10.1161/CIRCULATIONAHA.108. 844506 19414634
32. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Kanbay M, Nicoleta M, Selcoki Y, Ikizek M, Aydin M, Eryonucu B, Duranay M, Akcay A, Armutcu F, Covic A, Clin J Am Soc Nephrol 2010 5 1780 1786 10.2215/CJN.02560310 20576822
33. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Balci M, Kirkpantur A, Gulbay M, Gurbuz OA, Hemodial Int 2010 14 425 432 10.1111/j.1542-4758.2010.00480.x 20955275
34. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, J Am Soc Nephrol 2011 22 1913 1922 10.1681/ASN.2010121224 21903574
35. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner J, Wolf M, N Engl J Med 2008 359 584 592 10.1056/NEJMoa0706130 18687639
36. FGF23 induces left ventricular hypertrophy. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St Joh Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, et al. J Clin Invest 2011 121 4393 4408 10.1172/JCI46122 21985788
37. Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Smith K, Defilippi C, Isakova T, Gutierrez OM, Laliberte K, Seliger S, Kelley W, Duh SH, Hise M, Christenson R, Wolf M, Januzzi J, Am J Kidney Dis 2013 61 67 73 10.1053/j.ajkd.2012.06.022 22883134 Diseases Diseases Diseases Diseases Diseases Diseases Diseases Diseases